Who Paid My Doc
Efrain Montanez Morales
Dentist, Oral and Maxillofacial Surgery Cayey, PR Doctor of Dentistry
NPI 1750707832 CMS profile 6596849
20 Ave Antonio R Barcelo, Plaza Empresarial Municipal Suite 209, Cayey, PR 00736
General payments
$4,846
Research payments
$0
Ownership & investment interest
$0
Through program year 2021, Efrain Montanez Morales of Cayey, PR is reported in the CMS Open Payments database as having received $4,846 across 6 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 88th percentile of Dentist, Oral and Maxillofacial Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | General | $102 | 1 | |
| 2019 | General | $4,744 | 5 |
Beside peers
- Efrain Montanez Morales
- Dentist, Oral and Maxillofacial Surgery median
- Middle half of Dentist, Oral and Maxillofacial Surgery
- National median
In program year 2025, general payments to Efrain Montanez Morales were reported at $0. Among 3,834 Dentist, Oral and Maxillofacial Surgery profiles paid that year, the median was $150 and the middle half received between $56 and $423.
Show as a table
| Year | Efrain Montanez Morales | Dentist, Oral and Maxillofacial Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $4,744 | $142 | $50–$420 | $163 |
| 2020 | $0 | $96 | $36–$277 | $114 |
| 2021 | $102 | $138 | $45–$419 | $132 |
| 2022 | $0 | $144 | $48–$367 | $149 |
| 2023 | $0 | $153 | $55–$399 | $160 |
| 2024 | $0 | $152 | $50–$400 | $164 |
| 2025 | $0 | $150 | $56–$423 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
289
Drug cost
$1,909
Branded share of claims
4.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Amoxicillin | Generic | 115 | $853 | |
| Chlorhexidine Gluconate | Generic | 40 | $376 | |
| Ibuprofen | Generic | 49 | $223 | |
| Clindamycin Hcl | Generic | 13 | $179 | |
| Naproxen Sodium | Generic | 20 | $158 | |
| Alprazolam | Generic | 38 | $80 | |
| Midazolam Hcl Midazolam Hcl/Pf | Brand | 14 | $40 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,440 Part D prescribers listed as Oral Surgery (Dentist only); they describe a distribution and say nothing about conduct.
Records
6 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Dentist, Oral and Maxillofacial Surgery in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Dentist, Oral and Maxillofacial Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.